Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.55 |
| ▸ | MME | P08473 | 2/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30483839 | 0.92 | ENPEP (0.62) | ENPEPMMEACE | |
| SCHEMBL30799669 | 0.90 | BACE1 (0.55) | BACE1MMEACE | |
| SCHEMBL30799469 | 0.90 | MME (0.60) | ENPEPMMEACE | |
| SCHEMBL30898724 | 0.88 | MME (0.54) | OPRD1OPRM1OPRK1ENPEPMME | |
| SCHEMBL29968694 | 0.88 | BACE1 (0.54) | BACE1BACE2OPRD1OPRM1OPRK1 | |
| SCHEMBL30799807 | 0.88 | BACE1 (0.59) | BACE1BACE2OPRD1OPRM1OPRK1 | |
| SCHEMBL2549533 | 0.87 | MME (0.60) | OPRD1OPRM1OPRK1MMEACE | |
| SCHEMBL11799997 | 0.87 | MME (0.56) | MMEACE | |
| SCHEMBL30445690 | 0.87 | MME (0.60) | OPRD1OPRM1OPRK1MMEACE | |
| SCHEMBL30799883 | 0.87 | MME (0.56) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | disclosed |
| US-20250064792-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2025-02-27 | — | — | US | disclosed |
| US-20240216353-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-07-04 | — | — | US | disclosed |
| US-11918570-B2 | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230127290-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | SERPINB1, ELANE, CELA1 | BACE1 508/4885BACE2 2475/4885OPRD1 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.